MSN Labs/Novadoz Pharmaceuticals announces US FDA approval of Abiraterone.
M2 PHARMA-July 16, 2019-MSN Labs/Novadoz Pharmaceuticals announces US FDA approval of Abiraterone
(C)2019 M2 COMMUNICATIONS
Active pharmaceutical ingredients (API) company MSN Labs, the parent company of Novadoz Pharmaceuticals, reported on Monday the receipt of US FDA approval to market Abiraterone Acetate 250mg tablets in 120 tablet count bottles for the treatment of prostate cancer with a steroid medication (prednisone or methylprednisolone).
This US FDA approval marks the ninth since March 2018, when Novadoz began commercial operations as MSN Labs' US sales and marketing affiliate for their finished dosage forms.The company expects additional product launches over the next 12 months continuing the organization's meteoric entrance and rise in the US market.
Additionally, the Abiraterone Acetate 250mg tablets is the second oncology product launched by Novadoz.
The company added that the Abiraterone Acetate 250mg tablets are the generic version of Janssen Pharmaceuticals' product Zytiga.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 16, 2019|
|Previous Article:||Abbott wins US FDA approval of next-generation MitraClip under its leading MitraClip platform.|
|Next Article:||Medical Coaches to produce mobile opioid clinics in Colorado.|